Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Harish Potu"'
Autor:
Anupama Pal, Michele Dziubinski, Marina Pasca Di Magliano, Diane M. Simeone, Scott Owens, Dafydd Thomas, Luke Peterson, Harish Potu, Moshe Talpaz, Nicholas J. Donato
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 2, Pp 152-164 (2018)
Usp9x has emerged as a potential therapeutic target in some hematologic malignancies and a broad range of solid tumors including brain, breast, and prostate. To examine Usp9x tumorigenicity and consequence of Usp9x inhibition in human pancreatic tumo
Externí odkaz:
https://doaj.org/article/19db205bc2874616815167a39bc4e502
Autor:
Harish Potu, Luke F. Peterson, Malathi Kandarpa, Anupama Pal, Hanshi Sun, Alison Durham, Paul W. Harms, Peter C. Hollenhorst, Ugur Eskiocak, Moshe Talpaz, Nicholas J. Donato
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Usp9x is a deubiquitinating enzyme with altered expression in melanoma; however its functional contribution in this context is not clear. Here the authors show that Usp9x regulates the stability of the transcription factor Ets-1 that in turn impacts
Externí odkaz:
https://doaj.org/article/e602171c7095415dab7480a2914dff72
Supplementary Figures 1-5, Methods from Identification of USP18 as an Important Regulator of the Susceptibility to IFN-α and Drug-Induced Apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09107fd9e6898ae66584de177da9b98b
https://doi.org/10.1158/0008-5472.22383858.v1
https://doi.org/10.1158/0008-5472.22383858.v1
Gene products that modify the apoptotic susceptibility of cancer cells may offer novel drug response markers or therapeutic targets. In this study, we probed the contribution of 53 different isopeptidases to apoptosis triggered by bortezomib and etop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e269736f6f6001b974d4d048fd8e44f
https://doi.org/10.1158/0008-5472.c.6500685.v1
https://doi.org/10.1158/0008-5472.c.6500685.v1
1320 Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation
Autor:
Liang Lin, Vishal Khairnar, Harish Potu, Hao-Ming Chang, Elisabetta Burchi, Armin Rath, Stanley Frankel, Jean Kadouche, Daniel Teper, Wei Li, Antonio Arulanandam
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Malathi Kandarpa, Moshe Talpaz, Nicholas J. Donato, Alison B. Durham, Harish Potu, Luke F. Peterson
Publikováno v:
Oncotarget
Melanoma tumors driven by BRAF mutations often do not respond to BRAF/MEK/ERK pathway inhibitors currently used in treatment. One documented mechanism of resistance is upregulation of SOX2, a transcription factor that is essential for tumor growth an
Autor:
Antonio Arulanandam, Liang Lin, Hao-Ming Chang, Harish Potu, Vishal Khairnar, David Zou, Melissa Triggiano, Nejmi Dilmac, Yinan Yang, Shira Kahlon, Stanley Frankel, Jean Kadouche, Daniel Teper, Ofer Mandelboim, Yoav Hershkovitz, Yaron Ilan, Wei Li
Publikováno v:
Clinical Cancer Research. 28:PO001-PO001
BACKGROUND: GPC3 is highly expressed in HCC while it is hardly expressed in adult normal tissues except placenta. Given the presence of dysfunctional NK cells in the HCC tumor microenvironment that contribute to poor anti-tumor immune responses, we s
Publikováno v:
Oncotarget
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway has emerged as a cancer therapeutic target. However, clinical trials have proven that most human cancers are resistant to TRAIL. We show that exposure to recombinant TRAIL re
Autor:
Moshe Talpaz, Avery Polk, Luke F. Peterson, Malathi Kandarpa, Harish Potu, Yihong Liu, Shaomeng Wang
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S212
Mouse double minute 2 homolog (MDM2) is a E3 ubiquitin ligase that promotes p53 tumor suppressor degradation. MDM2 has emerged as a therapeutic target in the treatment of TP53 wild-type expressing acute myeloid leukemia (AML) where MDM2 is overexpres
Autor:
Moshe Talpaz, Malathi Kandarpa, Harish Potu, Avery Polk, Shaomeng Wang, Luke F. Peterson, Yihong Liu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S212
Bromodomain and Extra Terminal (BET) proteins are ubiquitously expressed epigenetic “readers” that play a major role in regulating expression of oncogenic genes such as c-Myc. BET protein family are crucial for acute myeloid leukemia (AML) mainte